This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
176
Viking Clinical Site #119
Birmingham, Alabama, United States
Viking Clinical Site #114
Long Beach, California, United States
Percent (relative) change from baseline to Week 13 in body weight
To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13
To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Viking Clinical Site #110
Los Angeles, California, United States
Viking Clinical Site #113
Tustin, California, United States
Viking Clinical Site #116
Clearwater, Florida, United States
Viking Clinical Site #106
Clearwater, Florida, United States
Viking Clinical Site #112
Jacksonville, Florida, United States
Viking Clinical Site #105
Ocoee, Florida, United States
Viking Clinical Site #107
Port Orange, Florida, United States
Viking Clinical Site #104
Indianapolis, Indiana, United States
...and 10 more locations